Immuneering (IMRX) Change in Accured Expenses (2020 - 2026)

Immuneering's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$247323.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 39.62% year-over-year to -$247323.0; the TTM figure through Mar 2026 stood at -$12341.0 (down 137.51% YoY), while the FY2025 annual figure was $57848.0, up 321.6% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$247323.0, down from $211424.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.1 million in Q2 2023, with the low at -$2.2 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $66608.0 (2024), against an average of $29350.7.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses soared 2432.12% in 2022, then tumbled 521.93% in 2025.
• Immuneering's Change in Accured Expenses stood at $430006.0 in 2022, then surged by 240.5% to $1.5 million in 2023, then plunged by 88.12% to $174008.0 in 2024, then climbed by 21.5% to $211424.0 in 2025, then sank by 216.98% to -$247323.0 in 2026.
• Business Quant data shows IMRX's Change in Accured Expenses at -$247323.0 in Q1 2026, $211424.0 in Q4 2025, and $304594.0 in Q3 2025.